May 13, 2021 08:01 AM EDTUpdated 09:59 AM
Pharma
FDA+

Third time’s the charm as Heron wins FDA nod for non-opi­oid anes­thet­ic Zyn­relef

Zachary Brennan

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

A service from the Financial Times